These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 31105021)
1. Potency test to discriminate between differentially over-inactivated rabies vaccines: Agreement between the NIH assay and a G-protein based ELISA. Toinon A; Moreno N; Chausse H; Mas E; Nicolai MC; Guinchard F; Jaudinaud I; Guinet-Morlot F; Riou P; Manin C Biologicals; 2019 Jul; 60():49-54. PubMed ID: 31105021 [TBL] [Abstract][Full Text] [Related]
2. G-protein based ELISA as a potency test for rabies vaccines. Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171 [TBL] [Abstract][Full Text] [Related]
3. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release. Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572 [TBL] [Abstract][Full Text] [Related]
4. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein. Soni D; Sahoo I; Mallya AD; Kamthe P; Sahai A; Goel SK; Kulkarni PS; Dhere RM J Immunol Methods; 2021 May; 492():112939. PubMed ID: 33309752 [TBL] [Abstract][Full Text] [Related]
5. Development of a relative potency test using ELISA for human rabies vaccines. Wang Z; Sun Y; Wu X; Carroll DS; Lv W; You L; Ji Y; Shi J; Yan J; Xu G; Meng S Biologicals; 2018 Sep; 55():59-62. PubMed ID: 29970288 [TBL] [Abstract][Full Text] [Related]
6. Development and pre-validation of a quantitative multi-dose serological assay for potency testing of inactivated rabies vaccines for human use. Moreira WC; Freitas JFS; Machado NS; Almeida AECC; Moura WC J Virol Methods; 2019 Jan; 263():54-59. PubMed ID: 30393149 [TBL] [Abstract][Full Text] [Related]
7. Establishment of a potency test by ELISA for a rabies vaccine for animal use in Japan. Gamoh K; Shimazaki Y; Senda M; Makie H; Itoh O; Muramatsu M; Hirayama N; Hatakeyama H J Vet Med Sci; 2003 Jun; 65(6):685-8. PubMed ID: 12867727 [TBL] [Abstract][Full Text] [Related]
8. A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use. Krämer B; Kamphuis E; Hanschmann KM; Milne C; Daas A; Duchow K Biologicals; 2013 Nov; 41(6):400-6. PubMed ID: 24144483 [TBL] [Abstract][Full Text] [Related]
9. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera. Thraenhart O; Ramakrishnan K J Biol Stand; 1989 Oct; 17(4):291-309. PubMed ID: 2613705 [TBL] [Abstract][Full Text] [Related]
10. Possibility of Immediate Introduction of a Single-Dose Antibody Induction Test as a Refinement of the NIH Test for Inactivated Rabies Vaccine Potency Determination. Stankov S; Obradović N; Vujin D; Vranješ N Viral Immunol; 2020 Jun; 33(5):367-377. PubMed ID: 32159457 [TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Rooijakkers E; Groen J; Uittenbogarrd J; van Herwijnen J; Osterhaus A Dev Biol Stand; 1996; 86():137-45. PubMed ID: 8785943 [TBL] [Abstract][Full Text] [Related]
12. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency. Jallet C; Tordo N J Vis Exp; 2020 May; (159):. PubMed ID: 32449742 [TBL] [Abstract][Full Text] [Related]
13. In vitro potency tests: challenges encountered during method development. Yomayuza CL; Thiel HJ; König M Dev Biol (Basel); 2012; 134():93-100. PubMed ID: 22888600 [TBL] [Abstract][Full Text] [Related]
14. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study. Morgeaux S; Poirier B; Ragan CI; Wilkinson D; Arabin U; Guinet-Morlot F; Levis R; Meyer H; Riou P; Shaid S; Volokhov D; Tordo N; Chapsal JM Vaccine; 2017 Feb; 35(6):966-971. PubMed ID: 28081969 [TBL] [Abstract][Full Text] [Related]
15. The rabies peripheral challenge test: more accurate determination of vaccine potency. Wunderli PS; Dreesen DW; Miller TJ; Baer GM Vaccine; 2006 Nov; 24(49-50):7115-23. PubMed ID: 16919854 [TBL] [Abstract][Full Text] [Related]
16. Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay. Moreira WC; Machado NS; Freitas JFS; Almeida AECC; Moura WC J Virol Methods; 2019 Feb; 264():31-37. PubMed ID: 30448319 [TBL] [Abstract][Full Text] [Related]
17. In vitro inactivation of the rabies virus by ascorbic acid. Madhusudana SN; Shamsundar R; Seetharaman S Int J Infect Dis; 2004 Jan; 8(1):21-5. PubMed ID: 14690777 [TBL] [Abstract][Full Text] [Related]
18. Potency testing of inactivated rabies vaccines using a serological method. Kamphuis E; Krämer B; Schildger H; Duchow K Dev Biol (Basel); 2012; 134():23-7. PubMed ID: 22888591 [TBL] [Abstract][Full Text] [Related]
19. Development of an assay for detecting the residual viable virus in inactivated rabies vaccine by enzyme-linked immunosorbent assay. Kawahara M; Takayama-Ito M; Kato H; Kitaura S; Satoh M; Saijo M Biologicals; 2021 Apr; 70():59-63. PubMed ID: 33518433 [TBL] [Abstract][Full Text] [Related]
20. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency. Lin G; Chen S; Zhao H; Liang J; Deng Q; Liang R; Guo X; Chen Z; Chen B; Liu T; Wu Y Sci Rep; 2017 Aug; 7(1):7288. PubMed ID: 28779162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]